MSLN and breast neoplasm: Similar results have been obtained using EVs that are derived from mesothelin (MSLN)-targeted CAR-T cells, showing their efficiency in targeting MSLN-positive and triple-negative breast cancer cells via secretion of perforin and granzyme B. More importantly, the study demonstrated a marked antitumor effect with low toxicity in vivo, in both BT-549 and MDA231-MSLN xenograft breast tumor models [142].